IL1R1 and rheumatoid arthritis: There is limited information on immunization responses in patients receiving anakinra, an IL-1 receptor antagonist approved for RA, the IL-1R-Accessory Protein fusion protein rilonacept, or the anti-IL1-β antibody canakinumab.